
Pharmacally
ORKA-001
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in ORKA-001
Mergers & AcquisitionsHalozyme Licenses Hypercon Technology to Oruka Therapeutics for ORKA-001Halozyme Therapeutics and Oruka Therapeutics have entered a global collaboration to use Hypercon™ drug delivery technology with ORKA-001, Oruka’s Phase 1 IL-23-targeting psoriasis candidate.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.